{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T13:44:47Z","timestamp":1782135887553,"version":"3.54.5"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T00:00:00Z","timestamp":1758585600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","nmd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuromuscular Disorders"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.nmd.2025.106221","type":"journal-article","created":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T19:20:54Z","timestamp":1758828054000},"page":"106221","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Applying the international rare disease research consortium (IRDiRC) N-of-1 therapy task force eligibility criteria for individualised therapies use case: Duchenne muscular dystrophy"],"prefix":"10.1016","volume":"55","author":[{"given":"Annemieke","family":"Aartsma-Rus","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anneliene H.","family":"Jonker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"O\u2019Connor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nmd.2025.106221_bib0001","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2024.1414658","article-title":"Antisense oligonucleotides and their applications in rare neurological diseases","volume":"18","author":"McDowall","year":"2024","journal-title":"Front Neurosci"},{"issue":"4","key":"10.1016\/j.nmd.2025.106221_bib0002","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1089\/nat.2023.0027","article-title":"From failure to meet the clinical endpoint to U.S. Food and Drug Administration approval: 15th antisense oligonucleotide therapy approved qalsody (Tofersen) for treatment of SOD1 mutated amyotrophic lateral sclerosis","volume":"33","author":"van Roon-Mom","year":"2023","journal-title":"Nucleic Acid Ther"},{"issue":"6","key":"10.1016\/j.nmd.2025.106221_bib0003","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1016\/j.ymthe.2025.04.038","article-title":"Clinical applications of exon-skipping antisense oligonucleotides in neuromuscular diseases","volume":"33","author":"Torres-Masjoan","year":"2025","journal-title":"Mol Ther"},{"issue":"4","key":"10.1016\/j.nmd.2025.106221_bib0004","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202013243","article-title":"Delivery of oligonucleotide-based therapeutics: challenges and opportunities","volume":"13","author":"Hammond","year":"2021","journal-title":"EMBO Mol Med"},{"issue":"6","key":"10.1016\/j.nmd.2025.106221_bib0005","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1093\/nar\/gkad067","article-title":"Chemistry, structure and function of approved oligonucleotide therapeutics","volume":"51","author":"Egli","year":"2023","journal-title":"Nucleic Acids Res"},{"issue":"2","key":"10.1016\/j.nmd.2025.106221_bib0006","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1089\/nat.2020.0845","article-title":"The 10th oligonucleotide therapy approved: golodirsen for Duchenne muscular dystrophy","volume":"30","author":"Aartsma-Rus","year":"2020","journal-title":"Nucleic Acid Ther"},{"key":"10.1016\/j.nmd.2025.106221_bib0007","doi-asserted-by":"crossref","DOI":"10.1177\/22143602251324858","article-title":"Antisense RNA therapies for muscular dystrophies","author":"Arechavala-Gomeza","year":"2025","journal-title":"J Neuromuscul Dis"},{"issue":"8","key":"10.1016\/j.nmd.2025.106221_bib0008","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkaf346","article-title":"The N=1 Collaborative: advancing customized nucleic acid therapies through collaboration and data sharing","volume":"53","author":"Belgrad","year":"2025","journal-title":"Nucleic Acids Res"},{"issue":"17","key":"10.1016\/j.nmd.2025.106221_bib0009","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1056\/NEJMoa1813279","article-title":"Patient-customized oligonucleotide therapy for a rare genetic disease","volume":"381","author":"Kim","year":"2019","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.nmd.2025.106221_bib0010","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/s41573-024-01059-3","article-title":"The state-of-the-art of N-of-1 therapies and the IRDiRC N-of-1 development roadmap","volume":"24","author":"Jonker","year":"2025","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.nmd.2025.106221_bib0011","article-title":"Joining forces to develop individualized antisense oligonucleotides for patients with brain or eye diseases: the example of the Dutch Center for RNA Therapeutics","volume":"5","author":"Aartsma-Rus","year":"2024","journal-title":"Ther Adv Rare Dis"},{"issue":"5","key":"10.1016\/j.nmd.2025.106221_bib0012","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1038\/s41591-025-03547-4","article-title":"The rare therapies launchpad: a pilot program for individualized medicines in the UK","volume":"31","author":"O'Connor","year":"2025","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.nmd.2025.106221_bib0013","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1089\/nat.2024.0091","article-title":"Addressing the needs of nano-rare patients","volume":"35","author":"Crooke","year":"2025","journal-title":"Nucleic Acid Ther"},{"issue":"6","key":"10.1016\/j.nmd.2025.106221_bib0014","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1038\/s41591-023-02335-2","article-title":"Personalized antisense oligonucleotides 'for free, for life' - the n-Lorem Foundation","volume":"29","author":"Gleeson","year":"2023","journal-title":"Nat Med"},{"issue":"10","key":"10.1016\/j.nmd.2025.106221_bib0015","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.1038\/s41591-024-03197-y","article-title":"Antisense oligonucleotide therapy in an individual with KIF1A-associated neurological disorder","volume":"30","author":"Ziegler","year":"2024","journal-title":"Nat Med"},{"issue":"7","key":"10.1016\/j.nmd.2025.106221_bib0016","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1038\/s41591-024-03078-4","article-title":"AAV gene therapy for hereditary spastic paraplegia type 50: a phase 1 trial in a single patient","volume":"30","author":"Dowling","year":"2024","journal-title":"Nat Med"},{"issue":"22","key":"10.1016\/j.nmd.2025.106221_bib0017","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1056\/NEJMoa2504747","article-title":"Patient-specific In vivo gene editing to treat a rare genetic disease","volume":"392","author":"Musunuru","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nmd.2025.106221_bib0018","article-title":"From roadmap to a sustainable end-to-end individualized therapy pathway","volume":"6","author":"Jonker","year":"2025","journal-title":"Ther Adv Rare Dis"},{"issue":"3","key":"10.1016\/j.nmd.2025.106221_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2025.102615","article-title":"Tailored antisense oligonucleotides for ultrarare CNS diseases: an experience-based best practice framework for individual patient evaluation","volume":"36","author":"Sch\u00fcle","year":"2025","journal-title":"Mol Ther Nucleic Acids"},{"issue":"1","key":"10.1016\/j.nmd.2025.106221_bib0020","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41572-021-00248-3","article-title":"Duchenne muscular dystrophy","volume":"7","author":"Duan","year":"2021","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"10.1016\/j.nmd.2025.106221_bib0021","doi-asserted-by":"crossref","DOI":"10.1002\/mgg3.510","article-title":"DMD open-access variant Explorer (DOVE): a scalable, open-access, web-based tool to aid in clinical interpretation of genetic variants in the DMD gene","volume":"7","author":"Bailey","year":"2019","journal-title":"Mol Genet Genomic Med"},{"issue":"3","key":"10.1016\/j.nmd.2025.106221_bib0022","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1002\/humu.20918","article-title":"Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations","volume":"30","author":"Aartsma-Rus","year":"2009","journal-title":"Hum Mutat"},{"issue":"2","key":"10.1016\/j.nmd.2025.106221_bib0023","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1089\/nat.2021.0039","article-title":"Preparing n-of-1 antisense oligonucleotide treatments for rare neurological diseases in Europe: genetic, regulatory, and ethical perspectives","volume":"32","author":"Synofzik","year":"2022","journal-title":"Nucleic Acid Ther"},{"issue":"7","key":"10.1016\/j.nmd.2025.106221_bib0024","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1007\/s40265-024-02052-1","article-title":"Givinostat: first approval","volume":"84","author":"Lamb","year":"2024","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.nmd.2025.106221_bib0025","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s40265-023-01986-2","article-title":"Vamorolone: first approval","volume":"84","author":"Keam","year":"2024","journal-title":"Drugs"},{"issue":"14","key":"10.1016\/j.nmd.2025.106221_bib0026","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1007\/s40265-023-01929-x","article-title":"Delandistrogene moxeparvovec: first approval","volume":"83","author":"Hoy","year":"2023","journal-title":"Drugs"},{"issue":"5","key":"10.1016\/j.nmd.2025.106221_bib0027","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000208112","article-title":"Efficacy and safety of vamorolone over 48 weeks in boys with duchenne muscular dystrophy: a randomized controlled trial","volume":"102","author":"Dang","year":"2024","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.nmd.2025.106221_bib0028","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S1474-4422(24)00036-X","article-title":"Safety and efficacy of givinostat in boys with Duchenne muscular dystrophy (EPIDYS): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"23","author":"Mercuri","year":"2024","journal-title":"Lancet Neurol"}],"container-title":["Neuromuscular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896625009484?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896625009484?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T03:54:22Z","timestamp":1764215662000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960896625009484"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":28,"alternative-id":["S0960896625009484"],"URL":"https:\/\/doi.org\/10.1016\/j.nmd.2025.106221","relation":{},"ISSN":["0960-8966"],"issn-type":[{"value":"0960-8966","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Applying the international rare disease research consortium (IRDiRC) N-of-1 therapy task force eligibility criteria for individualised therapies use case: Duchenne muscular dystrophy","name":"articletitle","label":"Article Title"},{"value":"Neuromuscular Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nmd.2025.106221","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"106221"}}